Lupin's Stock Hits 52-Week High; Thanks to the Launch of Darunavir Tablets

5 Jun 2023 , 11:38 AM

In the early trade on June 5, Lupin’s shares had gained nearly 2 percent and reached a 52-week high of Rs.830.30. The surge in share price was driven by the company’s announcement of the launch of Darunavir Tablets.

• Lupin introduced Darunavir Tablets in 600 mg and 800 mg strengths, serving as a generic equivalent of Prezista Tablets manufactured by Janssen Products, LP.
• The estimated annual sales of Darunavir Tablets in the US are USD 308 million.
• The launch of Darunavir Tablets is expected to contribute significantly to Lupin’s growth in the market.

Strong Financial Performance and Market Response: Lupin reported a consolidated net profit of Rs.236 crore for the January-March quarter, a significant turnaround from the net loss incurred in the same period last year. The company’s topline grew by 12.1 % year-on-year to reach Rs.4,330.3 crore in the fourth quarter. Lupin’s EBIDTA margin expanded by 690 basis points to 14.2 % in Q4 FY22. The positive financial performance and product launches contributed to the rise in Lupin’s share price.

At the time of writing, Lupin’s share price was trading at Rs.820.95 or 0.47% in BSE.